Baudax Bio rises on positive data from muscle relaxant drug's mid-stage trial

Baudax Bio

25/04/2023 14:02

** Shares of drug developer Baudax Bio Inc  BXRX.O  rise
42.6% at $2.70 in premarket trading
    ** Co reports positive final results from mid-stage trial of
its experimental drug being tested for use as a neuromuscular
blockade (NMB) in patients undergoing elective surgery
    ** NMBs, or muscle relaxants, are used at the beginning of
surgery to help doctors insert a breathing tube
    ** BX1000 is a NMB which helps doctors intubate, or insert a
breathing tube in patients, during surgery
    ** BX1000 in the study met primary study goal of "good or
excellent" intubating conditions at 60 seconds, co cites 
    ** A total of 80 patients were treated in the study and no
severe adverse events were observed in any dose regimen 
    ** Co targets marketing application submission for BX1000,
to the U.S. FDA by about year-end 2025
    ** BXRX stock was down 40.9% YTD, as of last close 

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))